基质金属蛋白酶抑制因子-2基因-418G/C多态性与房颤性脑梗死患者出血转化风险的相关研究  

Association between TIMP-2(-418G/C)polymorphism and the risk of hemorrhagic transformation in patients with cerebral infarction due to atrial fibrillation

作　　者：李卫玲[1] 金笑平[1] 虞丹[1] 沈玉光 LI Weiling;JIN Xiaoping;YU Dan(Department of Neurology,Taizhou Hospital,Taizhou 317000,China)

机构地区：[1]台州医院神经内科,317000

出　　处：《心电与循环》2020年第3期227-231,共5页Journal of Electrocardiology and Circulation

基　　金：浙江省公益基金项目(LGF18H090019)。

摘　　要：目的研究基质金属蛋白酶抑制因子-2(TIMP-2)基因-418G/C多态性与房颤性脑梗死出血转化风险的相关性。方法272例房颤性脑梗死患者,根据是否发生出血转化,分为出血转化组63例(23.2%),非出血转化组209例(76.8%),采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法分析TIPM-2基因启动子区-418G/C的多态性。结果出血转化组GC+CC基因型频率39.7%,非出血转化组45.9%,两组比较差异无统计学意义(OR=0.864,P>0.05),C等位基因频率在两组间分别为24.6%和28.0%,差异无统计学意义(OR=0.879,P>0.05)。经logistic回归分析,首次收缩压(OR=1.034,95%CI:1.004~1.069,P<0.05)、美国国立卫生院卒中量表(NIHSS)评分(OR=1.364,95%CI:1.187~1.569,P<0.01)是房颤性脑梗死患者出血转化的危险因素。结论TIMP-2基因-418G/C位点的多态性与房颤性脑梗死出血转化无关。Objective To investigate the association between matrix metalloproteinase inhibitor-2(TIMP-2)gene(-418G/C)polymorphisms and the risk of hemorrhagic transformation of ischemic stroke due to atrial fibrillation(AF).Methods 272 patients with acute cerebral infarction due to AF were included,of them,63 cases(23.2%)were complicated with hemorrhagic transformation.Polymerase chain reaction-restriction fragment length polymorphism method was used to analyze TIMP-2 gene promoter(-418G/C)polymorphism.Results There was no significant difference of frequency of the GC+CC genotypes and C allele in patients with and without hemorrhagic transformation(39.7%vs.45.9%,24.6%vs.28.0%,all P>0.05).Logistic regression analysis showed that the first systolic blood pressure(OR=1.034,95%CI:1.004~1.069,P<0.05)and NIHSS score(OR=1.364,95%CI:1.187~1.569,P<0.01)were risk factors of hemorrhagic transformation in patients with cerebral infarction due to AF.Conclusion TIMP-2 gene(-418G/C)polymorphisms is not associated with hemorrhagic transformation of cerebral infarction due to AF.

关 键 词：基质金属蛋白酶抑制因子-2 房颤 缺血性脑梗死 基因多态性 出血转化 

分 类 号：R743.33[医药卫生—神经病学与精神病学]